Purple Biotech (PPBT) Common Equity (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Common Equity data on file, last reported at $9.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $9.7 million, down 70.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.7 million (down 70.22% YoY), and the FY2025 annual result was $9.7 million, down 70.48% from the prior year.
• Common Equity held at $9.7 million in Q1 2026 per PPBT's latest filing, from $9.7 million in the prior quarter.
• Over five years, Common Equity peaked at $58.1 million in Q1 2022 and troughed at $9.7 million in Q4 2025.
• A 5-year average of $36.1 million and a median of $32.9 million in 2024 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 11.43% in 2025 and fell as far as 70.48% in 2025.
• A 5-year view of Common Equity shows it stood at $47.1 million in 2022, then retreated by 27.18% to $34.3 million in 2023, then declined by 4.04% to $32.9 million in 2024, then sank by 70.48% to $9.7 million in 2025, then gained by 0.08% to $9.7 million in 2026.
• Business Quant data shows PPBT's Common Equity at $9.7 million in Q1 2026, $9.7 million in Q4 2025, and $32.8 million in Q3 2025.